Stock Analysis

Medicure Full Year 2024 Earnings: CA$0.10 loss per share (vs CA$0.088 loss in FY 2023)

TSXV:MPH
Source: Shutterstock
Advertisement

Medicure (CVE:MPH) Full Year 2024 Results

Key Financial Results

  • Revenue: CA$21.9m (up 1.0% from FY 2023).
  • Net loss: CA$1.04m (loss widened by 13% from FY 2023).
  • CA$0.10 loss per share (further deteriorated from CA$0.088 loss in FY 2023).
We've discovered 2 warning signs about Medicure. View them for free.
earnings-and-revenue-history
TSXV:MPH Earnings and Revenue History April 30th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Medicure shares are up 14% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for Medicure that you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSXV:MPH

Medicure

A biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States.

Flawless balance sheet and good value.

Similar Companies

Advertisement